Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study-Reference-Cited by-同舟云学术

Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study

Published:2004-08 Issue:8 Volume:15 Page:1173-1178
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Fleming G.F.,Filiaci V.L.,Bentley R.C.,Herzog T.,Sorosky J.,Vaccarello L.,Gallion H.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/15/8/1173/335816/mdh316.pdf

Reference33 articles.

1. Chemotherapy of metastatic endometrial cancer;Muss;Semin Oncol,1994

2. Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions;Moore;J Clin Oncol,1991

3. Phase III trial of doxorubicin +/− cisplatin advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group (GOG) study;Thigpen;Proc Am Soc Clin Oncol,1993

4. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomized study (55872) by the EORTC Gynaecological Cancer Group;Aapro;Ann Oncol,2003

5. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group study;Gallion;J Clin Oncol,2003

Cited by 184 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Redefining the Position of Hormonal Therapy in Endometrial Cancer in the Era of Molecular Classification;Journal of Clinical Oncology;2024-01-01

2. Association Between Intermediate End Points, Progression-free Survival, and Overall Survival in First-line Advanced or Recurrent Endometrial Cancer;Clinical Therapeutics;2023-10

3. Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma;Expert Review of Anticancer Therapy;2023-03-28

4. Heterogeneity of outcomes of endometrial cancer patients included in prospective clinical trials;Gynecologic Oncology;2023-02

5. Adenocarcinoma of the uterine corpus and sarcomas of the uterus;DiSaia and Creasman Clinical Gynecologic Oncology;2023